Millendo Therapeutics (NASDAQ:MLND) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a sell rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

Other research analysts also recently issued reports about the company. ValuEngine downgraded Welbilt from a hold rating to a sell rating in a research report on Wednesday, June 12th. Citigroup set a $12.00 price target on Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a research report on Monday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $24.38.

NASDAQ MLND traded up $0.05 during trading on Tuesday, hitting $10.70. The company’s stock had a trading volume of 4,660 shares, compared to its average volume of 106,299. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $12.68. The firm has a market cap of $141.89 million, a price-to-earnings ratio of -0.61 and a beta of 2.61. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34.

Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). As a group, analysts predict that Millendo Therapeutics will post -3.27 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MLND. BlackRock Inc. bought a new stake in shares of Millendo Therapeutics during the fourth quarter valued at about $203,000. Geode Capital Management LLC bought a new stake in shares of Millendo Therapeutics during the fourth quarter valued at about $113,000. Worth Venture Partners LLC bought a new stake in shares of Millendo Therapeutics during the fourth quarter valued at about $206,000. Great Point Partners LLC bought a new stake in shares of Millendo Therapeutics during the fourth quarter valued at about $10,240,000. Finally, Tibra Equities Europe Ltd bought a new stake in shares of Millendo Therapeutics during the first quarter valued at about $303,000. Institutional investors and hedge funds own 44.07% of the company’s stock.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.